Friedhelm Bladt is a Senior Director and Global Biomarker Leader at Bayer Pharmaceuticals, where they currently lead the global biomarker initiatives for the Radiopharmaceutical platform. With extensive experience in pre-clinical and clinical translational research, Friedhelm has successfully driven projects from discovery to proof-of-concept across various organizations, including Merck Group and sanofi-aventis. They have also contributed significantly to the development of innovative technological platforms in oncology and have mentored teams in both laboratory settings and collaborative external partnerships. Friedhelm holds a PhD in Molecular Biology from the University of Cologne, where they also earned a Master's degree in Chemistry.
This person is not in the org chart
This person is not in any teams
This person is not in any offices